{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-045067","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.228663+00:00","generated_at":"2026-05-22T10:30:54.236501+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Rigel Q1 net income $11.4M vs loss; revenue $53.3M (+68% YoY); 2025 outlook reaffirmed","bullets":["Net product sales $43.6M up 68% YoY: TAVALISSE $28.5M (+35%), GAVRETO $9.0M, REZLIDHIA $6.1M (+25%).","R289 granted FDA Orphan Drug (MDS) and Fast Track (lower-risk MDS); Phase 1b enrolling sixth dose level.","Patent settlement with Annora allows generic TAVALISSE license in Q2 2032 or earlier; litigation terminated.","Will not opt-in for ocadusertib; expects $40M non-cash revenue in Q2 from release of cost-share liability.","2025 outlook: total revenue $200-210M (excl. $40M one-time); positive net income expected for full year."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-045067","json":"https://secwatch.observer/filing/0001104659-25-045067.json","markdown":"https://secwatch.observer/filing/0001104659-25-045067.md","text":"https://secwatch.observer/filing/0001104659-25-045067.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465925045067/0001104659-25-045067-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465925045067/tm2514128d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T10:30:54.236501+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}